Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

BioAge Labs, Inc. Common Stock

BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Our proprietary platform encompasses >65M molecular measurements spanning 45+ years of human aging and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. Our growing clinical-stage portfolio includes BGE-105, a first-in-class apelin receptor agonist that prevented muscle atrophy in a Ph1b study of older volunteers at bedrest. We are developing BGE-105 in parallel for ICU-related atrophies and for muscle preservation during GLP-1 weight loss therapy. The portfolio also includes novel internally discovered NLRP3 inhibitors for neurodegenerative and ocular diseases driven by inflammation. Our mission is to develop therapies that change the nature of aging and provide patients with years more healthy time. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.

BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development.

At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.


AME Cloud Ventures

Andreessen Horowitz

Felicis

Pear VC

Redpoint

Bossanova Investimentos

Caffeinated Capital

Kaiser Foundation Hospitals

Elad Gil

Ling Wong

BioAge Labs

BioAge is pleased to announce plans to initiate a Phase 2 trial of our apelin receptor agonist azelaprag co-administered with tirzepatide for treatment of obesity. Under the terms of an agreement signed yesterday, Eli Lilly and Company will provide tirzepatide for the study, and Lilly’s Chorus organization will advise and assist BioAge on trial design and execution. The trial, planned to start in mid-2024, is designed to assess whether this drug combination can achieve increased overall weight loss with improved body composition.

https://lnkd.in/gnpq_Juh

👇🏼 Keep reading for more background & why we’re excited for the trial:

• Azelaprag is an oral drug for the future of obesity therapy: Co-administration has the potential to achieve best-in-class weight loss with next-generation oral incretins currently in the pipeline, whose performance lags behind injectables. Our goal is 20–25% healthy weight loss with a completely oral drug combination.

• We are collaborating with a global leader in obesity: We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s experience in obesity drug development. We are proud to collaborate with Lilly in one of their most important and competitive areas. 

• Our promising preclinical data points to greater — and healthier — weight loss: In diet-induced obese (DIO) mice, co-administration with azelaprag substantially increased weight loss achieved on tirzepatide alone. In addition, the combination normalized body composition to that of lean controls and decreased blood glucose levels

• Apelin signaling has been demonstrated to have multiple benefits for energy metabolism — and in our Phase 1b trial, azelaprag promoted muscle metabolism and protein synthesis while being well tolerated in healthy volunteers. 	

• The planned trial will advance BioAge’s mission of extending healthy lifespan in a new indication: Treating obesity has the potential to prevent or delay multiple diseases of aging for a large segment of the population.


Learn more about azelaprag, the apelin pathway, and obesity on our website:
https://lnkd.in/gSRkyM-t


BioAge is proud to sponsor Longevity Global’s 2024 SF kickoff event on Tuesday, Jan 30: afternoon co-working at the beautiful Savills space in downtown San Francisco, followed by lightning pitches and networking over drinks and food. Bring your laptop and co-work with friends (1–5 pm), and then pitch your longevity idea in the early evening (5–7:30).

See invite for details: https://lu.ma/f1mtzklu
Registration is free for first-time attendees of Longevity SF events.

See you there!

We got 2024 off to a great start with BioAge’s annual panel discussion & reception during JPM Healthcare Week. In a conversation moderated by BioAge CEO Kristen Fortney, panelists Tracey McLaughlin (Professor, Stanford University School of Medicine), Rob Myers, MD (CMO, OrsoBio), Michael Davidson (CEO, NewAmsterdam Pharma), and Axel Haupt (Senior Vice President, Diabetes Clinical Development, Eli Lilly and Company) shared their thoughts on our theme of “Extending human healthspan: Obesity, metabolism, and aging”.

Key takeaways from their conversation:

✅ Many pathways link obesity, metabolic disorders, and aging — and targeting these common pathways may have benefits for treating chronic disease.

✅ Emerging drug targets like apelin, FGF21, CETP inhibitors, and others have effects on aging pathways as well as specific diseases like obesity, diabetes, and CVD. Combination therapies may have synergistic benefits.

✅ Challenges in studying drugs for prevention include long trial durations, the need for large sample sizes, identification of appropriate biomarkers, and lack of reimbursement incentives. Regulators and stakeholders need to collaborate on solutions.

✅ Biomarkers are advancing: lipids and CRP have potential for tracking metabolic health; advanced imaging may eventually be accepted for showing benefits on atherosclerosis; and Alzheimer's disease trials are moving towards biomarker-based approvals.

✅ Key upcoming readouts will provide more evidence on whether incretins and new mechanisms can improve cardiovascular and kidney outcomes. Studies on preserving muscle mass with weight loss and combination approaches for obesity are important.

✅ Precision medicine approaches, targeting treatments based on disease subtypes and underlying physiology, will come to the fore as the cardiometabolic space attracts more attention and resources. 

Many thanks to our brilliant panelists — and to all who attended and created such an enjoyable evening!

📸 Action shot! At abcam's 2023 Innate Sensing & Signaling in Immunology meeting in Boston this week, BioAge scientists Kevin Wilhelmsen, Sarah Tronnes, and Aditi Deshpande presented a poster on our novel class of NLRP3 inflammasome inhibitors, which we are developing for inflammatory and age-related diseases. 

BioAge’s AI-driven discovery platform revealed that NLRP3 levels rise with age and are positively correlated with all-cause mortality. To identify novel NLRP3 inhibitors, we screened billions of molecules in a DNA-encoded library (DEL) for compounds that bind purified NLRP3 protein, yielding drug-like compounds that functionally inhibit the NLRP3 inflammasome in vitro with comparable or superior potency relative to publicly known inhibitors.

https://lnkd.in/gmUffkJD

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '22	Dec '23
revenue	2.67M -	1.54M 42.10%	2.17M 40.76%	8.27M 280.88%	14.94M 80.63%
cost of revenue	2.69M -	6.04M 124.76%	2.61M 56.77%	13.67M 423.08%	22.32M 63.34%
gross profit	-23.78K -	-4.50M 18,824.99%	-440.83K 90.21%	-5.39M 1,123.71%	-7.38M 36.82%
selling and marketing expenses	4.73M -	4.48M 5.24%	4.00M 10.70%	2.91M 27.16%	1.94M 33.49%
general and administrative expenses	5.03M -	6.17M 22.80%	6.59M 6.79%	6.54M 0.75%	10.41M 59.13%	9.45M 9.27%	14.51M 53.64%
selling general and administrative expenses	9.76M -	10.66M 9.20%	10.59M 0.57%	9.46M 10.73%	12.35M 30.58%	9.45M 23.51%	14.51M 53.64%
research and development expenses	16.58M -	15.16M 8.59%	20.29M 33.85%	7.20M 64.53%	5.47M 24.02%	30.52M 458.28%	33.89M 11.02%
other expenses	14.82M -	4.89M 66.98%	7.21M 47.30%	7.58M 5.20%	84.82M 1,018.57%
cost and expenses	43.85M -	36.75M 16.19%	40.70M 10.76%	37.90M 6.87%	124.96M 229.68%	39.97M 68.01%	48.40M 21.09%
operating expenses	41.16M -	30.70M 25.40%	38.09M 24.05%	24.24M 36.37%	102.63M 323.48%	39.97M 61.06%	48.40M 21.09%
interest expense	-7.43M -					241K -	7.79M 3,134.02%
ebitda	-38.84M -	-44.98M 15.80%	-33.07M 26.48%	-13.29M 59.81%	-88.72M 567.55%	-39.38M 55.62%	-45.81M 16.34%
operating income	-41.18M -	-35.20M 14.51%	-38.53M 9.44%	-29.63M 23.10%	-110.01M 271.29%	-39.97M 63.67%	-48.40M 21.09%
depreciation and amortization	1.71M -	1.37M 19.84%	4.16M 204.39%	9.16M 120.21%	9.35M 2.01%	129K 98.62%	162K 25.58%
total other income expenses net	7.49M -	-12.02M 260.40%	-2.65M 77.98%	1.28M 148.57%	7.91M 515.46%	23K 99.71%	-10.09M 43,973.91%
income before tax	-33.69M -	-47.22M 40.17%	-41.17M 12.81%	-28.35M 31.16%	-102.11M 260.22%	-39.72M 61.10%	-63.85M 60.75%
income tax expense	102.79K -	75.37K 26.68%	-3.79K 105.02%	25.65K 777.39%	81.73K 218.70%	241K 194.86%	7.79M 3,134.02%
net income	-33.22M -	-46.42M 39.75%	-37.23M 19.81%	-22.48M 39.62%	-98.15M 336.65%	-39.72M 59.53%	-63.85M 60.75%
weighted average shs out	15.59M -	20.02M 28.38%	24.50M 22.40%	28.67M 17.00%	41.95M 46.34%
weighted average shs out dil	28.18M -	28.18M 0%	28.18M 0%	34.19M 21.32%	41.95M 22.69%
eps	-2.13 -	-2.32 8.92%	-1.52 34.48%	-0.78 48.68%	-2.34 200.00%	0 100%	0
epsdiluted	-1.18 -	-1.65 39.83%	-1.32 20.00%	-0.66 50%	-2.34 254.55%	0 100%	0

BIOA

COM:BIOAGELABS

BioAge Labs

Last Close

19.14

22/11 21:00

Market Cap

220.11M

Beta: -

Volume Today

157.82K

Avg: -

Preview